Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Curr Neurol Neurosci Rep
; 17(9): 67, 2017 Sep.
Article
em En
| MEDLINE
| ID: mdl-28735353
ABSTRACT
PURPOSE OF REVIEW An 80-year-old man presents with an acute right hemiparesis and National Institutes of Health Stroke Scale (NIHSS) of 25, 14 h after taking dabigatran. Activated partial thromboplastin time (aPTT) is 42.8 s. Arteriogram demonstrates left internal carotid artery thrombosis. What is the appropriate management of this patient with acute ischemic stroke while on a NOAC? RECENT FINDINGS:
Idarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs. In this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vitamina K
/
Acidente Vascular Cerebral
/
Anticoagulantes
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article